Eli Lilly

Novo Nordisk is launching its new weight loss pill in the United Arab Emirates as part of a global rollout. The company aims to regain market position against rival Eli Lilly in the weight loss drug sector.

Lawmakers are urging the U.S. Department of Health and Human Services to force Eli Lilly to reinstate 340B drug discounts to hospitals. The company stopped offering discounts to 50 hospital systems that failed to comply with a new policy requiring claims data sharing. Lawmakers argue Lilly's actions violate federal law by eliminating mandated price breaks.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.

Northwestern State University's proposed law school faces stalled approval despite President Jimmy Genovese's efforts, while Medicare begins covering GLP-1 weight-loss drugs for obesity treatment. The Trump administration plans to allocate $500 million to support smaller meatpackers amid high beef prices.

Eli Lilly has transferred sales rights for the breast cancer drug Verzenios in mainland China to Innovent Biologics. Innovent will manage importing, marketing, and distribution as generic competition emerges.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

The FDA has selected Eli Lilly and Regeneron for its PreCheck program, which aims to expedite domestic drug factory reviews by assessing facilities during construction. The program could save participating companies up to 14 months in review time.

Medicare will begin covering obesity drugs for the first time, potentially expanding access for seniors and creating new patient opportunities for Novo Nordisk and Eli Lilly.

The Trump administration's deal with Eli Lilly and Novo Nordisk on GLP-1 drugs aimed for lower Medicare/Medicaid prices in exchange for higher sales volume, but companies secured higher sales without lowering prices in some cases. The $245 monthly price was contingent on private insurers covering the drugs with a $50 copay, a condition not publicly disclosed by the administration.

The FDA has launched a pilot program with Eli Lilly and Regeneron to accelerate the development and approval of U.S. drug manufacturing facilities by engaging companies during design and construction phases. The initiative aims to reduce delays, improve compliance, and strengthen the domestic pharmaceutical supply chain to reduce reliance on overseas production.

Eli Lilly and Regeneron are among the first seven companies selected by the FDA for its PreCheck Pilot Program, an initiative aimed at accelerating the review of new manufacturing facilities. The program was reported by CNBC.

Medicare will cover weight-loss drugs for the first time starting July 1 through a temporary pilot program called Medicare GLP-1 Bridge. The program aims to reduce costs for medications like Zepbound and Wegovy, which are expensive without insurance, providing financial relief for seniors like Mary and Jeff Abrahamson who previously relied on compounded versions of tirzepatide.

Seniors in Medicare will gain landmark obesity drug coverage starting July 1, but many may remain unaware due to limited government and company advertising.

Shares of AbbVie, Eli Lilly, and Johnson & Johnson were on track to hit all-time highs Friday, signaling renewed investor interest in the biopharmaceutical sector. Healthcare stocks are becoming a refuge for investors shifting away from technology stocks.

Most U.S. stocks rose Friday as oil prices retreated from wartime highs, but declines in AI stocks limited gains. The S&P 500 remained nearly flat, on track for its second weekly loss in 13 weeks due to AI sector pressures. Health care stocks gained after European drug approval recommendations, while United Airlines and Eli Lilly rose on lower oil costs and regulatory news.

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are expected to increase consumer demand, but employer-sponsored health insurance plans may not cover the costs of these medications.

A 79-year-old patient with obesity, sleep apnea, and pulmonary hypertension received Eli Lilly's experimental drug retatrutide under a compassionate use program. The White House denied the drug was for President Trump after initial speculation.

Insurance companies are increasingly dropping coverage for weight loss drugs like Wegovy and Zepbound due to rising costs, pushing patients to purchase through telehealth providers or manufacturers. Hims partners with Wegovy to offer the drug directly, while CVS expands coverage for Eli Lilly's anti-obesity pill and reinstates Zepbound later this year.

Eli Lilly's obesity drug retatrutide is being made available to one individual through the FDA's 'compassionate use' program. The article discusses this development alongside broader questions about drugmaker acquisitions and the investment potential of hair loss drugs, as covered in a podcast episode.

Eli Lilly is investing $40 million in Absci, an AI startup developing treatments for hair loss and endometriosis. Absci raised $100 million in total funding led by Eli Lilly, with the startup publicly traded on Nasdaq.

The White House denied that Trump gained access to Eli Lilly's unapproved obesity drug retatrutide through a compassionate use program. The drug, not yet FDA approved, is available via a program that provides experimental treatments for life-threatening illnesses.

The White House denied a report suggesting President Trump received the investigational obesity drug retatrutide. STAT reported that Eli Lilly and the FDA approved a compassionate use request for the medication.

Eli Lilly and Bayer criticize Germany's spending on new medicines. Pharmaceutical groups support the US's opposition to legislation aimed at lowering drug prices.

A man was granted compassionate-use access to an experimental GLP-1 drug developed by Eli Lilly. The exclusive report details the sole individual given special access to the obesity treatment, as covered in STAT's health policy newsletter.

Eli Lilly and the FDA have allowed one person to receive the company's obesity drug retatrutide through the FDA's 'compassionate use' program. The access was granted via an exclusive report by Lizzy Lawrence.

Eli Lilly provided access to its experimental obesity drug retatrutide to a 79-year-old man through the FDA’s compassionate use program. The case drew interest from top health officials, suggesting the recipient was well connected.

Eli Lilly, the maker of Mounjaro, is using funds from its weight-loss drug to develop an 'App Store' for scientists. The company is collaborating with small biotechs to leverage AI as a tool for drug discovery.

Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.

Pharmaceutical companies are developing drugs to preserve muscle mass during weight loss, addressing an issue with existing GLP-1 drugs like Ozempic. Candidates such as bimagrumab, SPX-001, and CagriSema aim to reduce fat while retaining lean mass, with Cambrian Biotech testing a drug that mimics exercise to boost metabolism.

Elite colleges are losing public trust due to economic challenges and AI-driven job changes, creating opportunities for community colleges and certification programs. Indianapolis Public Schools and partners like IU Indianapolis and Eli Lilly demonstrate pathways to career readiness through partnerships and dual-credit programs. Education leaders emphasize personalized college counseling and transparent financial commitments to attract students.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

Eli Lilly reduced the price of its weight-loss drug Mounjaro in Brazil by up to 36% through a loyalty program, with starter packs dropping from R$3,350 to R$2,250. Some drug combinations saw price cuts exceeding R$2,000, triggering a price war in Brazil's weight-loss drug market.

A study by the National Bureau of Economic Research found that middle-aged adults using GLP-1 drugs for obesity could save $192,735 in lifetime medical costs on average, with higher savings ($220,000) for those without college degrees. The study attributes these savings to GLP-1s' direct impact on appetite and metabolism, which benefits individuals with limited time for diet/exercise regimens.

Drugmakers are competing to enter the obesity drug market currently dominated by Novo Nordisk and Eli Lilly. The article highlights the pharmaceutical industry's interest in this lucrative sector.

Abridge, a health tech startup, has partnered with NVIDIA and Eli Lilly to develop an AI-native clinician intelligence platform that streamlines clinical documentation, billing, and pharmaceutical trial screening. The platform, used by over 300 health systems, captures real-time patient-clinician conversations and has raised $1.1 billion, including a $316 million Series E extension. NVIDIA is co-developing a foundation model for clinical dialogue, while Eli Lilly aligns with its AI-driven healthcare initiatives.

Abridge, a health care AI company, announced strategic partnerships with Eli Lilly and Nvidia to develop a clinical AI model and streamline healthcare operations. The deals aim to enhance clinical workflows and address the limitations of generic AI in healthcare.

Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.